专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5602151A Cholesterol ester hydrolase inhibitors 失效
标题翻译：胆固醇酯水解酶抑制剂
公开(公告)号：US5602151A
公开(公告)日：1997-02-11
申请号：US572993
申请日：1995-12-15
申请人： Richard E. Mewshaw , Thomas J. Commons , Donald P. Strike
发明人： Richard E. Mewshaw , Thomas J. Commons , Donald P. Strike
IPC分类号： C07C271/40 , C07D295/205 , A61K31/445 , C07D211/06
CPC分类号： C07D295/205 , C07C271/40 , C07C2101/14 , C07C2103/93
摘要： The compounds of the formula: ##STR1## in which X is ##STR2## where R.sup.7 is hydrogen, alkyl, hydroxy, alkanoyloxy, hydroxyalkyl, hydroxycarbonyl, alkoxycarbonyl, phenyl or substituted phenyl, in which the substituent is alkyl, alkoxy, halo, nitro, cyano, haloalkyl, perhaloalkyl or dialkylaminoalkyl; R.sup.8 is hydrogen or alkyl or R.sup.7 and R.sup.8 taken together are polymethylene; R.sup.9 is hydrogen, alkyl, phenyl or substituted phenyl, in which the substituent is alkyl, alkoxy, halo, nitro, cyano or perhaloalkyl; R.sup.10 is hydrogen, alkyl or gemdialkyl; n is one of the integers 0, 1 or 2; and R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are, independently, hydrogen, alkyl, alkoxy, halo, nitro, cyano or perhaloalkyl, alkoxycarbonyl or hydroxycarbonyl; and when X is --NR.sup.9 -- or R.sup.7 is an amino alkyl group, a pharmaceutically acceptable salt thereof; are useful as inhibitors of cholesterol ester hydrolase.
摘要翻译：其中X为的化合物，其中R 7为氢，烷基，羟基，烷酰氧基，羟基烷基，羟基羰基，烷氧基羰基，苯基或取代的苯基，其中取代基为烷基，烷氧基，卤素，硝基，氰基，卤代烷基，全卤代烷基或二烷基氨基烷基; R8是氢或烷基或R7和R8一起是聚亚甲基; R9是氢，烷基，苯基或取代的苯基，其中取代基是烷基，烷氧基，卤素，硝基，氰基或全卤代烷基; R10为氢，烷基或偕二烷基; n是整数0,1或2之一; 并且R 3，R 4，R 5和R 6独立地为氢，烷基，烷氧基，卤素，硝基，氰基或全卤代烷基，烷氧基羰基或羟基羰基。当X是-NR9-或R7是氨基烷基时，其药学上可接受的盐; 可用作胆固醇酯水解酶的抑制剂。

2. 发明授权

US5512565A Cholesterol ester hydrolase inhibitors 失效
标题翻译：胆固醇酯水解酶抑制剂
公开(公告)号：US5512565A
公开(公告)日：1996-04-30
申请号：US413559
申请日：1995-03-30
申请人： Richard E. Mewshaw , Thomas J. Commons , Donald P. Strike
发明人： Richard E. Mewshaw , Thomas J. Commons , Donald P. Strike
IPC分类号： C07C271/40 , C07D295/205 , A61K31/54 , C07D279/12
CPC分类号： C07D295/205 , C07C271/40 , C07C2101/14 , C07C2103/93
摘要： The compounds of the formula: ##STR1## in which ##STR2## where R.sup.7 is hydrogen, alkyl, hydroxy, alkanoyloxy, hydroxyalkyl, hydroxycarbonyl, alkoxycarbonyl, phenyl or substituted phenyl, in which the substituent is alkyl, alkoxy, halo, nitro, cyano, haloalkyl, perhaloalkyl or dialkylaminoalkyl; R.sup.8 is hydrogen or alkyl or R.sup.7 and R.sup.8 taken together are polymethylene; R.sup.9 is hydrogen, alkyl, phenyl or substituted phenyl, in which the substituent is alkyl, alkoxy, halo, nitro, cyano or perhaloalkyl; R.sup.10 is hydrogen, alkyl or gemdialkyl; n is one of the integers 0, 1 or 2; and R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are, independently, hydrogen, alkyl, alkoxy, halo, nitro, cyano or perhaloalkyl, alkoxycarbonyl or hydroxycarbonyl; and when X is --NR.sup.9 -- or R.sup.7 is an amino alkyl group, a pharmaceutically acceptable salt thereof; are useful as inhibitors of cholesterol ester hydrolase.
摘要翻译：其中R7是氢，烷基，羟基，烷酰氧基，羟基烷基，羟基羰基，烷氧基羰基，苯基或取代的苯基，其中取代基是烷基，烷氧基，卤素，硝基，氰基，卤代烷基，全卤代烷基或二烷基氨基烷基; R8是氢或烷基或R7和R8一起是聚亚甲基; R9是氢，烷基，苯基或取代的苯基，其中取代基是烷基，烷氧基，卤素，硝基，氰基或全卤代烷基; R10为氢，烷基或偕二烷基; n是整数0,1或2之一; 并且R 3，R 4，R 5和R 6独立地为氢，烷基，烷氧基，卤素，硝基，氰基或全卤代烷基，烷氧基羰基或羟基羰基。当X是-NR9-或R7是氨基烷基时，其药学上可接受的盐; 可用作胆固醇酯水解酶的抑制剂。

3. 发明授权

US4994486A Dopaminergic compounds 失效
标题翻译：多巴胺能化合物
公开(公告)号：US4994486A
公开(公告)日：1991-02-19
申请号：US456011
申请日：1989-12-22
申请人： Robert W. Schoenleber , John W. Kebabian , Michael P. DeNinno , Michael R. Michaelides , Sheela A. Thomas
发明人： Robert W. Schoenleber , John W. Kebabian , Michael P. DeNinno , Michael R. Michaelides , Sheela A. Thomas
IPC分类号： A61K38/00 , C07C41/02 , C07C215/64 , C07C217/74 , C07C219/28 , C07C233/18 , C07C237/08 , C07C271/16 , C07C271/44 , C07C309/65 , C07C323/60 , C07D207/08 , C07D209/62 , C07D221/10 , C07D221/20 , C07D311/76 , C07D311/78 , C07D311/96 , C07D313/08 , C07D405/04 , C07D405/06 , C07D405/12 , C07D407/04 , C07D407/12 , C07D493/10 , C07K5/06
CPC分类号： C07D207/08 , C07C215/64 , C07C217/74 , C07C219/28 , C07C233/18 , C07C237/08 , C07C271/16 , C07C271/44 , C07C309/65 , C07C323/60 , C07D209/62 , C07D221/10 , C07D221/20 , C07D311/76 , C07D311/78 , C07D311/96 , C07D313/08 , C07D405/04 , C07D405/06 , C07D405/12 , C07D407/04 , C07D407/12 , C07D493/10 , C07K5/06026 , A61K38/00 , C07C2101/14 , C07C2102/10 , C07C2102/28 , C07C2103/28 , C07C2103/74 , C07C2103/93
摘要： Novel compounds of Formula (I): ##STR1## or pharmaceutically acceptable salts, esters and amides thereof, wherein A is O, C, CH or CH.sub.2, n is 0 or 1, and the dotted line is a single bond when A is O or CH.sub.2 and a double bond when A is CH or when n=0, A is C andR.sub.6 and A taken together form a nitrogen-containing heterocycle;R is hydrogen, lower alkyl or a readily cleavable group;R.sub.1 is selected from hydrogen, halogen, lower alkyl, haloalkyl and lower alkoxy;R.sub.2 is selected from hydrogen, halogen, lower alkyl and haloalkyl or, taken together with R.sub.8, forms a fused ring;R.sub.3 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl or arylalkyl or, taken together with R.sub.4, forms a spirocycloalkyl or, taken together with R.sub.5, forms a fused cycloalkyl;R.sub.4 is hydrogen or alkyl or, taken together with R.sub.3, forms a spirocycloalkyl;R.sub.5 is hydrogen or alkyl or, taken together with R.sub.3, forms a fused cycloalkyl;R.sub.6 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or arylalkyl or, taken together with A when A is C and when n is 0, forms a fused nitrogen-containing heterocycle or, taken together with R.sub.7 or R.sub.8, forms a nitrogen-containing heterocycle;R.sub.7 is hydrogen or alkyl or, taken together with R.sub.6 or R.sub.8, forms a nitrogen-containing heterocycle;R.sub.8 is hydrogen or alkyl or, taken together with R.sub.6 or R.sub.7, forms a nitrogen-containing heterocycle or, taken together with R.sub.2, forms a fused ring, with the proviso that R.sub.3 and R.sub.4 cannot simultaneously both be hydrogen, are selective dopaminergic agents and are useful for treating disorders characterized by abnormal dopaminergic activity in the central or the peripheral nervous system, for example, neurological disorders such as psychoses, Parkinson's Disease, certain cardiovascular disorders and addictive behavior disorders.
摘要翻译：式（I）的新型化合物：其中A为O，C，CH或CH 2，n为0或1，虚线为单键， A为O或CH2，当A为CH或当n = 0时为双键，A为C且R6和A一起形成含氮杂环; R是氢，低级烷基或易裂解基团; R1选自氢，卤素，低级烷基，卤代烷基和低级烷氧基; R2选自氢，卤素，低级烷基和卤代烷基，或与R8一起形成稠环; R 3是氢，烷基，烯基，炔基，环烷基，芳基或芳烷基，或与R 4一起形成螺环烷基，或与R 5一起形成稠合环烷基; R4是氢或烷基，或与R3一起形成螺环烷基; R5是氢或烷基，或与R3一起形成稠合的环烷基; R 6是氢，烷基，烯基，炔基，环烷基或芳基烷基，或者当A是C时，与A一起，当n是0时，形成稠合含氮杂环，或者与R 7或R 8一起形成含氮杂环 R7是氢或烷基，或与R6或R8一起形成含氮杂环; R8是氢或烷基，或与R6或R7一起形成含氮杂环，或者与R2一起形成稠合环，条件是R3和R4不能同时为氢，是选择性多巴胺能试剂，可用于治疗以中枢或周围神经系统异常多巴胺能活性为特征的疾病，例如神经系统疾病如精神病，帕金森病，某些心血管疾病和成瘾行为障碍。

4. 发明授权

US4963568A Dopamine agonists 失效
标题翻译：多巴胺激动剂
公开(公告)号：US4963568A
公开(公告)日：1990-10-16
申请号：US359448
申请日：1989-05-31
申请人： Robert W. Schoenleber , John W. Kebabian , Yvonne C. Martin , Michael P. DeNinno , Richard J. Perner , David M. Stout , Chi-Nung W. Hsiao , Stanley DiDomenico, Jr. , John F. DeBernardis , Fatima Z. Basha , Michael D. Meyer , Biswanath De
发明人： Robert W. Schoenleber , John W. Kebabian , Yvonne C. Martin , Michael P. DeNinno , Richard J. Perner , David M. Stout , Chi-Nung W. Hsiao , Stanley DiDomenico, Jr. , John F. DeBernardis , Fatima Z. Basha , Michael D. Meyer , Biswanath De
IPC分类号： A61K31/13 , A61K31/135 , A61K31/16 , A61K31/335 , A61K31/40 , A61K31/403 , A61K31/404 , A61K38/00 , A61P9/00 , A61P25/00 , A61P25/18 , A61P25/30 , C07C41/02 , C07C215/48 , C07C215/64 , C07C217/56 , C07C217/74 , C07C219/28 , C07C233/18 , C07C237/08 , C07C271/16 , C07C271/44 , C07C309/65 , C07C323/60 , C07D207/08 , C07D209/08 , C07D209/62 , C07D221/06 , C07D221/10 , C07D221/20 , C07D311/76 , C07D311/78 , C07D311/96 , C07D313/08 , C07D405/04 , C07D405/06 , C07D405/12 , C07D407/04 , C07D407/12 , C07D493/10 , C07K5/06
CPC分类号： C07D207/08 , C07C215/64 , C07C217/74 , C07C219/28 , C07C233/18 , C07C237/08 , C07C271/16 , C07C271/44 , C07C309/65 , C07C323/60 , C07D209/62 , C07D221/10 , C07D221/20 , C07D311/76 , C07D311/78 , C07D311/96 , C07D313/08 , C07D405/04 , C07D405/06 , C07D405/12 , C07D407/04 , C07D407/12 , C07D493/10 , C07K5/06026 , A61K38/00 , C07C2101/14 , C07C2102/10 , C07C2102/28 , C07C2103/28 , C07C2103/74 , C07C2103/93
摘要： Novel compounds which are selective dopamine agonists are useful for treating disorders characterized by abnormal dopamine levels, such as Parkinson's Disease, as well as cardiovascular disorders.
摘要翻译：作为选择性多巴胺激动剂的新型化合物可用于治疗以异常多巴胺水平为特征的疾病，例如帕金森病，以及心血管疾病。

5. 发明授权

US5591884A Dopamine agonists 失效
标题翻译：多巴胺激动剂
公开(公告)号：US5591884A
公开(公告)日：1997-01-07
申请号：US461330
申请日：1995-06-05
申请人： Michael P. DeNinno , Richard J. Perner
发明人： Michael P. DeNinno , Richard J. Perner
IPC分类号： A61K38/00 , C07C41/02 , C07C215/44 , C07C215/64 , C07C217/74 , C07C219/28 , C07C233/18 , C07C237/08 , C07C271/16 , C07C271/44 , C07C309/65 , C07C323/60 , C07D207/08 , C07D209/62 , C07D221/10 , C07D221/20 , C07D311/76 , C07D311/78 , C07D311/96 , C07D313/08 , C07D405/04 , C07D405/06 , C07D405/12 , C07D407/04 , C07D407/12 , C07D493/10 , C07K5/06 , C07F5/04 , C07C43/205 , C07C49/105
CPC分类号： C07D207/08 , C07C215/44 , C07C215/64 , C07C217/74 , C07C219/28 , C07C233/18 , C07C237/08 , C07C271/16 , C07C271/44 , C07C309/65 , C07C323/60 , C07D209/62 , C07D221/10 , C07D221/20 , C07D311/76 , C07D311/78 , C07D311/96 , C07D313/08 , C07D405/04 , C07D405/06 , C07D405/12 , C07D407/04 , C07D407/12 , C07D493/10 , C07K5/06026 , A61K38/00 , C07C2101/14 , C07C2102/10 , C07C2102/28 , C07C2103/28 , C07C2103/74 , C07C2103/93
摘要： Novel compounds having the formula ##STR1## and the pharmaceutically acceptable salts, esters and amides thereof, whereinA is --O--, --S-- or --CR.sup.2 R.sup.8 --;R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, X and Y are specifically defined; andup to one combination of (a) R.sup.2 and R.sup.5, (b) R.sup.5 and R.sup.6, (c) R.sup.5 and R.sup.7, (d) R.sup.6 and R.sup.7, and (e) R.sup.7 and Y, taken together with the atoms to which they are attached, may form a ring, the compounds being useful for treating dopamine-related neurological, psychological and cardiovascular disorders as well as in the treatment of cognitive impairment, attention deficit disorder, and substance abuse and other addictive behavior disorders.Also disclosed are intermediates and processes useful in the preparation of the above compounds.
摘要翻译：具有式的新化合物及其药学上可接受的盐，酯和酰胺，其中A是-O - ， - S-或-CR 2 R 8 - ; R1，R2，R3，R4，R5，R6，R7，R8，R9，R10，X和Y具体定义; 和（a）R2和R5的组合，（b）R5和R6，（c）R5和R7，（d）R6和R7，和（e）R7和Y与它们可以形成环，该化合物可用于治疗多巴胺相关的神经系统，心理和心血管疾病以及治疗认知障碍，注意力缺陷障碍以及药物滥用和其他成瘾行为障碍。还公开了可用于制备上述化合物的中间体和方法。

6. 发明授权

US5391571A Cholesterol ester hydrolase inhibitors 失效
标题翻译：胆固醇酯水解酶抑制剂
公开(公告)号：US5391571A
公开(公告)日：1995-02-21
申请号：US62026
申请日：1993-05-13
申请人： Richard E. Mewshaw , Thomas J. Commons , Donald P. Strike
发明人： Richard E. Mewshaw , Thomas J. Commons , Donald P. Strike
IPC分类号： C07C271/40 , C07D295/205 , A61K31/325 , C07C271/02
CPC分类号： C07D295/205 , C07C271/40 , C07C2101/14 , C07C2103/93
摘要： The compounds of the formula: ##STR1## in which R.sup.1 is alkyl of 4 or more carbon atoms, cycloalkyl, 1-adamantyl, 2-adamantyl, 3-noradamantyl, 3-methyl-1-adamantyl, 1-fluorenyl, 9-fluorenyl, cycloalkylalkyl, phenyl, substituted phenyl, alkyl, alkoxy, halo, nitro, cyano or trifluoromethyl, phenylalkyl or substituted phenylalkyl, where the substituent on the benzene ring is alkyl, alkoxy, halo, nitro, cyano, trifluoromethyl or phenyl; R.sup.2 is hydrogen, alkyl or R.sup.1 taken with R.sup.2 and the nitrogen atom to which they are attached form a heterocyclic moiety of the formula: ##STR2## wherein ##STR3## in which R.sup.7 is hydrogen, alkyl, hydroxy, alkanoyloxy, hydroxyalkyl, hydroxycarbonyl, alkoxycarbonyl, phenyl or substituted phenyl, in which the substituent is alkyl, alkoxy, halo, nitro, cyano, haloalkyl, perhaloalkyl or dialkylaminoalkyl; R.sup.8 is hydrogen or alkyl or R.sup.7 and R.sup.8 taken together are polymethylene; R.sup.9 is hydrogen, alkyl, phenyl or substituted phenyl, in which the substituent is alkyl, alkoxy, halo, nitro, cyano or perhaloalkyl; R.sup.10 is hydrogen, alkyl or gemdialkyl; n is one of the integers 0, 1 or 2; and R.sup.3, R.sup.4, R5 and R.sup.6 are, independently, hydrogen, alkyl, alkoxy, halo, nitro, cyano or perhaloalkyl, alkoxycarbonyl or hydroxycarbonyl; and when X is --NR.sup.9 -- or R.sup.7 is an amino alkyl group, a pharmaceutically acceptable salt thereof; useful as inhibitors of cholesterol ester hydrolase.
摘要翻译：下式的化合物：其中R1是4个或更多个碳原子的烷基，环烷基，1-金刚烷基，2-金刚烷基，3-降金刚烷基，3-甲基-1-金刚烷基，1-芴基，9-芴基烷基，烷氧基，卤素，硝基，氰基或三氟甲基，苯基烷基或取代的苯基烷基，其中苯环上的取代基是烷基，烷氧基，卤素，硝基，氰基，三氟甲基或苯基; R 2是氢，烷基或R 1与R 2取代，并且与它们相连的氮原子形成下式的杂环部分：其中R7是氢，烷基，羟基，烷酰氧基，羟基烷基，羟基羰基，烷氧基羰基，苯基或取代的苯基，其中取代基是烷基，烷氧基，卤素，硝基，氰基，卤代烷基，全卤代烷基或二烷基氨基烷基; R8是氢或烷基或R7和R8一起是聚亚甲基; R9是氢，烷基，苯基或取代的苯基，其中取代基是烷基，烷氧基，卤素，硝基，氰基或全卤代烷基; R10为氢，烷基或偕二烷基; n是整数0,1或2之一; 并且R 3，R 4，R 5和R 6独立地为氢，烷基，烷氧基，卤素，硝基，氰基或全卤代烷基，烷氧基羰基或羟基羰基。当X是-NR9-或R7是氨基烷基时，其药学上可接受的盐; 可用作胆固醇酯水解酶的抑制剂。

7. 发明专利

JP6077550B2 ポリイミド及びその製造に用いる脂環式テトラカルボン酸二無水物有权
标题翻译：在聚酰亚胺和其制备中所用的脂环族四羧酸二酐
公开(公告)号：JP6077550B2
公开(公告)日：2017-02-08
申请号：JP2014533068
申请日：2013-08-29
申请人： JXエネルギー株式会社
发明人：小松伸一 , 藤代理恵子 , 藤原実希 , 渡部大輔 , 椎橋彬 , 松本隆也
IPC分类号： C08L79/08 , C09D179/08 , G02F1/1337 , H05K1/03 , G02B5/10 , C07D493/10 , C08G73/10
CPC分类号： C08G73/1067 , C07D493/10 , C08G73/10 , C08G73/1007 , C08G73/1075 , C08G73/1078 , C07C2103/93

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式